NCT02052609View on ClinicalTrials.gov

A Phase 3 Clinical Study of KHK 4827

PHASE3CompletedINTERVENTIONAL
Enrollment

155

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

January 28, 2015

Study Completion Date

July 4, 2016

Conditions
Psoriasis VulgarisPsoriatic ArthritisPustular; Psoriasis, Palmaris Et PlantarisPsoriatic Erythroderma
Interventions
DRUG

KHK4827 140mg SC

Experimental1:KHK4827 140mg subcutaneous injection

DRUG

KHK4827 210mg SC

Experimental2:KHK4827 210mg subcutaneous injection

Trial Locations (1)

100-8185

For additional information regarding investigative sites for this trial, contact Kyowa Kirin, Chiyoda-ku

All Listed Sponsors
lead

Kyowa Kirin Co., Ltd.

INDUSTRY

NCT02052609 - A Phase 3 Clinical Study of KHK 4827 | Biotech Hunter | Biotech Hunter